PMID- 31516564
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 18
IP  - 4
DP  - 2019 Oct
TI  - Cross-disease analysis identified novel common genes for both lung adenocarcinoma 
      and lung squamous cell carcinoma.
PG  - 3463-3470
LID - 10.3892/ol.2019.10678 [doi]
AB  - Lung squamous cell carcinoma (LSCC) exhibits a number of similarities with lung 
      adenocarcinoma (LA) in terms of copy number alterations. However, compared with 
      LA, the range of genetic alterations in LSCC is less understood. In the present 
      study, a large-scale literature-based search of LA-associated genes and 
      LSCC-associated genes was performed to identify the genetic basis in common with 
      these two diseases. For each of the LA-associated genes, a mega-analysis was 
      performed to test its expression variations in LSCC using 11 RNA expression 
      datasets, with significant genes identified using statistical analysis. 
      Subsequently, a functional pathway analysis was performed to identify a possible 
      association between any of the significant genes identified from the 
      mega-analysis and LSCC, followed by a co-expression analysis. A multiple linear 
      regression (MLR) model was employed to investigate the possible influence of 
      sample size, country of origin and study date on gene expression in patients with 
      LSCC. Disease-gene association data analysis identified 1,178 genes involved in 
      LA, 334 in LSCC, with a significant overlap of 187 genes (P<1.02x(-161)). 
      Mega-analysis revealed that three LA-associated genes, such as solute carrier 
      family 2 member 1 (SLC2A1), endothelial PAS domain protein 1 (EPAS1) and 
      cyclin-dependent kinase 4 (CDK4), were significantly associated with LSCC 
      (P<1.60x10(-8)), with multiple potential pathways identified by functional 
      pathway analysis, which were further validated by co-expression analysis. The 
      present MLR analysis suggested that the country of origin was a significant 
      factor for the levels of expression of all three genes in patients with LSCC 
      (P<4.0x10(-3)). Collectively, the present results suggested that genes associated 
      with LA should be further investigated for their association with LSCC. In 
      addition, SLC2A1, EPAS1 and CDK4 may be novel risk genes associated with LA and 
      LSCC.
FAU - Zhang, Guanghui
AU  - Zhang G
AD  - Department of Cardiothoracic Surgery, Ningbo Fourth Hospital, Ningbo, Zhejiang 
      315037, P.R. China.
FAU - Wang, Weijie
AU  - Wang W
AD  - Department of Cardiothoracic Surgery, Ningbo Fourth Hospital, Ningbo, Zhejiang 
      315037, P.R. China.
FAU - Huang, Weiyang
AU  - Huang W
AD  - Department of Cardiothoracic Surgery, Ningbo Fourth Hospital, Ningbo, Zhejiang 
      315037, P.R. China.
FAU - Xie, Xiaoli
AU  - Xie X
AD  - Department of Cardiothoracic Surgery, Ningbo Fourth Hospital, Ningbo, Zhejiang 
      315037, P.R. China.
FAU - Liang, Zhigang
AU  - Liang Z
AD  - Department of Thoracic Surgery, Ningbo First Hospital, Ningbo, Zhejiang 315000, 
      P.R. China.
FAU - Cao, Hongbao
AU  - Cao H
AD  - Statistical Genomics and Data Analysis Core, National Institutes of Health, 
      Bethesda, MD 20852, USA.
LA  - eng
PT  - Journal Article
DEP - 20190729
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC6732964
OTO - NOTNLM
OT  - cyclin-dependent kinase 4
OT  - endothelial PAS domain protein 1
OT  - lung adenocarcinoma
OT  - lung squamous cell carcinoma
OT  - solute carrier family 2 member 1
EDAT- 2019/09/14 06:00
MHDA- 2019/09/14 06:01
PMCR- 2019/07/29
CRDT- 2019/09/14 06:00
PHST- 2018/09/06 00:00 [received]
PHST- 2019/05/25 00:00 [accepted]
PHST- 2019/09/14 06:00 [entrez]
PHST- 2019/09/14 06:00 [pubmed]
PHST- 2019/09/14 06:01 [medline]
PHST- 2019/07/29 00:00 [pmc-release]
AID - OL-0-0-10678 [pii]
AID - 10.3892/ol.2019.10678 [doi]
PST - ppublish
SO  - Oncol Lett. 2019 Oct;18(4):3463-3470. doi: 10.3892/ol.2019.10678. Epub 2019 Jul 
      29.